Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
ID: 353801Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353801

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the Small Business Transition Grant for New Entrepreneurs, aimed at supporting early-career scientists in their transition to entrepreneurship. This funding opportunity focuses on facilitating the development of small business concerns (SBCs) by providing mentorship, entrepreneurial training, and resources for Program Directors/Principal Investigators (PDs/PIs) who have limited experience in entrepreneurship but possess strong research and technology development skills. The grant is designed to enhance innovation and improve health outcomes by fostering the commercialization of scientific advancements, with applications accepted from U.S. small businesses until April 5, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-133-Full-Announcement.html
    Please provide the text you would like summarized.
    PAR-24-133.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) for the Small Business Transition Grant for New Entrepreneurs, aimed at facilitating early-career scientists' transition to entrepreneurship. This initiative emphasizes research and development activities while providing mentorship and entrepreneurial training for Program Directors/Principal Investigators (PDs/PIs). Eligible applicants include U.S. small business concerns led by individuals with limited entrepreneurial experience. The grant supports Phase I and Fast-Track applications but excludes those proposing clinical trials. Key components of the program include strong mentorship, a tailored career development plan focusing on entrepreneurial skill enhancement, and a commitment to fostering diversity in the scientific workforce. Application deadlines range from September 2024 to April 2027, with specific budget guidelines for Phase I and Phase II projects. NIH encourages applicants to engage with program officials beforehand to ensure alignment with NIH priorities and to explore available resources for successful applications. This funding opportunity seeks to promote innovation, improve health outcomes, and commercialize scientific advancements.
    Similar Opportunities
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)" to support early-career scientists in their transition to entrepreneurship. This grant aims to facilitate the development of small business concerns (SBCs) by employing researchers as Program Directors/Principal Investigators (PDs/PIs), providing them with essential entrepreneurial training, mentorship, and a structured framework for developing commercially viable biomedical technologies. The program is particularly focused on enhancing the entrepreneurial skills of scientists with strong technical expertise but limited experience in entrepreneurship, thereby aligning with NIH's mission to improve health. Interested applicants must be U.S.-based small businesses, and the application process will commence in September 2024, with a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) to support early-career scientists transitioning into entrepreneurship. This funding opportunity aims to facilitate the development of promising technologies by small business concerns (SBCs) while providing mentorship and entrepreneurial training for Program Directors/Principal Investigators (PDs/PIs) who are new to research entrepreneurship. The initiative is designed to enhance the biomedical workforce by coupling scientific expertise with essential business skills, ultimately contributing to public health advancements. Applications are invited for SBIR Phase I and Fast-Track grants, with deadlines ranging from September 2024 to April 2027. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-131.html.
    Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), has announced the Innovation Corps (I-Corps) at NIH Program, aimed at enhancing the commercialization of biomedical innovations from Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I projects. This program provides administrative supplement awards to eligible small business concerns, facilitating entrepreneurship training and assisting teams in refining their commercialization strategies through customer discovery activities over an eight-week course. With a total funding pool of up to $2.64 million available for up to 48 awards, individual grants are capped at $55,000, and applications must be submitted by January 31, 2025. Interested applicants are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further guidance before applying.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) to support pre-clinical research aimed at bridging funding gaps that impede the commercialization of medical biotechnology products. This funding opportunity specifically targets previously funded SBIR or STTR Phase II projects, with the objective of advancing products or technologies that require federal regulatory approval, while fostering partnerships between small businesses and external investors to enhance commercialization prospects. Applicants are encouraged to secure independent third-party funding that equals or exceeds one-third of the requested NINDS funds, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in the research environment. The application deadline is April 5, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html.